Hypoparathyroidism: an update on new therapeutic approaches

被引：0

作者：

Pitea, Marco ^{[1
]}

Lanzafame, Ruggero ^{[1
]}

Sala, Elisa ^{[1
]}

Croce, Ludovica ^{[1
]}

Mora, Stefano ^{[1
,2
]}

机构：

[1] IRCCS Osped San Raffaele, Dept Pediat, Milan, Italy

[2] IRCCS Osped San Raffaele, Lab Pediat Endocrinol, Milan, Italy

来源：

ENDOCRINE | 2025年 / 87卷 / 02期

关键词：

Parathyroid hormone; Hypoparathyroidism; Treatment; Autosomal dominant hypocalcemia; PARATHYROID-HORMONE; 1-34; REPLACEMENT THERAPY; TRIAL; PTH; AUTOTRANSPLANTATION; MICROENCAPSULATION; CALCITRIOL; INJECTIONS; CHILDREN; CALCIUM;

D O I：

10.1007/s12020-024-04057-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BackgroundHypoparathyroidism is a rare endocrine disease characterized by insufficient parathyroid hormone (PTH) secretion by the parathyroid glands, leading to hypocalcemia. In contrast to most hormone deficiencies for which hormone replacement is currently the mainstay of therapy, hypoparathyroidism has conventionally been treated with calcium supplements and active analogs of vitamin D. Although the advent of a replacement therapy with 1-34 and 1-84 PTH represented a major step in the therapeutic history of hypoparathyroidism, several new molecules and different management strategies have recently been developed.PurposeThis review investigates the therapeutic approaches currently under investigation for the treatment of hypoparathyroidism. Clinical trials results have been considered and discussed.

引用

页码：420 / 429

页数：10